#386 - Aging clocks—what they measure, how they work, and their clinical and real-world relevance
whatshot 153 snips
Apr 6, 2026
A deep dive into aging clocks, DNA methylation, and the difference between chronological age, biological age, and aging speed. It explores why these tools fascinate researchers, how newer clocks try to predict lifespan and decline, and why noisy data can muddy the picture. Two major studies add intrigue, including lifestyle interventions, brain MRI, dementia risk, and mortality.
55:34
forum Ask episode
web_stories AI Snips
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
insights INSIGHT
Why Aging Clocks Became Popular Proxies
Aging clocks matter because real anti-aging trials would need 20 years to measure heart attacks, cancer, dementia, and death.
Peter Attia frames clocks as needed proxies that could compress long outcomes into faster signals for trials and individual feedback.
insights INSIGHT
How DNA Methylation Powers Aging Clocks
Epigenetic clocks use DNA methylation at CpG sites because methylation shifts with age and reflects gene-expression control.
First-generation clocks like Horvath mainly predicted chronological age accurately, which proved concept but added little clinical value.
insights INSIGHT
Why Newer Clocks Are Hard to Interpret
Newer clocks try to predict biological age or pace of aging, but their signals can mix true aging with smoking, inflammation, or recent illness.
Peter Attia says both biological noise and lab measurement noise can shift results before any real health change occurs.
Get the Snipd Podcast app to discover more snips from this episode
In this episode, Peter takes a deep dive into the science and application of aging clocks, unpacking what they are, the differences between chronological age, biological age, and the pace of aging, and what epigenetic clocks may actually be measuring. He explores key research in the field, including a randomized controlled trial that tested simple lifestyle interventions against several commonly used aging clocks, as well as a study using brain MRI to assess the pace of aging and its relationship to dementia risk and mortality. Throughout the episode, Peter highlights the promises and pitfalls of these tools, ultimately focusing on the field's central question: whether improving an aging clock score truly translates into meaningful clinical outcomes.
We discuss:
Why aging clocks are being used as proxies for long-term health outcomes and the uncertainty surrounding their clinical value [2:00];
How aging clocks use DNA methylation to predict age and how they compare to traditional mortality prediction models [5:00];
The shift from aging clocks that predict chronological age to newer models that aim to measure biological age, lifespan differences, and the pace of aging [11:45];
The limitations of second-generation aging clocks: biological and measurement noise affecting reliability and interpretation [14:45];
Why aging clocks are exciting tools—compression, speed, and individual feedback [17:15];
The DO-HEALTH randomized trial: the study design and how different aging clocks were used to measure biological age and the pace of aging [22:00];
The DO-HEALTH study results: findings, takeaways, and open questions [27:45];
The DunedinPACNI study: how the model was developed and what it may add to the field [35:00];
The promise and limitations of aging clocks in measuring meaningful biological aging and predicting health outcomes [48:00];
Why aging clocks are not yet reliable as consumer tools and why traditional health metrics still matter most [52:00]; and
The Peter Attia Drive